Table S1 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Phosphoproteins

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Xiaoqing Cheng (16918496) (author)
Eará dahkkit:	Yirui Sun (16918499) (author), Maureen Highkin (16918502) (author), Nagalaxmi Vemalapally (16918505) (author), Xiaohua Jin (16918508) (author), Brandon Zhou (16918511) (author), Julie L. Prior (16918514) (author), Ashley R. Tipton (16918517) (author), Shunqiang Li (15123195) (author), Anton Iliuk (16918520) (author), Samuel Achilefu (11605234) (author), Ian S. Hagemann (15026769) (author), John R. Edwards (16918523) (author), Ron Bose (15045749) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Antireceptors Breast Cancer Cell Cycle CDKs and CDK inhibitors Preclinical Models Organoids
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance